Get started
Hims & Hers Health, Inc.Hims & Hers Health, Inc.Hims & Hers Health, Inc.

Hims & Hers Health, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

HIMS trade ideas

HIMS - June 24 (Broken Characters WIP)This is based on a new strategy that I started working on based on monitoring the larger price landscape and then observe character changes in the price action at key points. First new high Initial spike was brought about by news that HIMS would be launching its own branded GLP-1 medicines. These are the revolutionary weight loss drugs like Ozempic. Second new high Strong price movement with long full candles, but volume has slightly decreased. Third new high Price movement is dulling with significantly smaller candles and low voume Placed a small short bet that I will scale up if things go my way. Risk reward is good at 2.47 SL is based on me adding the ATR value on top of my entry What I am conflicted about is that the larger market regime is bullish
NYSE:HIMSShort
by Ronin_trader
1
Shares of Hims & Hers Health ($HIMS) Stock Surge 30% Digital pharmacy startup Hims & Hers Health ( NYSE:HIMS ) is introducing compounded GLP-1 weight loss injections, which have been gaining popularity due to supply constraints in the market. The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December but did not include GLP-1 medications such as Ozempic and Wegovy. Customers can access the compounded GLP-1 medications via a prescription from a licensed healthcare provider on the Hims & Hers platform. Hims & Hers ( NYSE:HIMS ) CEO Andrew Dudum said that the company is "confident" that customers will be able to access a consistent supply of the compounded medications. The company's oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month. The company expects its weight loss program to bring in more than $100 million in revenue by the end of 2025. The GLP-1 market, dominated by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as drugs like Ozempic and Wegovy continue to skyrocket in popularity. The FDA does not review the safety and efficacy of compounded products, which are custom-made alternatives to brand drugs designed to meet a specific patient's needs. In a January release, the FDA said patients should not use a compounded GLP-1 drug if an approved drug, such as Wegovy, is available. Hims & Hers ( NYSE:HIMS ) Health's stock price is doing well, thanks to its strong growth and demand for its core products. It has surged by over 30% this year and by more than 112% this year, giving it a market cap of $3.13 billion. Hims & Hers Health's ( NYSE:HIMS ) business released data this month showing that its total revenue soared by 46% in Q1 to over $278 million, and its subscribers roared by 41% to 1.7 million. This performance makes it one of the fastest-growing companies in the US. Hims & Hers ( NYSE:HIMS ) expects revenue growth between $292 million and $297 million in Q2 while the adjusted EBITDA will be between $30 and $30 million. The company focuses on some of the biggest industries globally, including sex, anxiety, weight loss, hair, and skin, each of which has a total addressable market worth billions of dollars. Analysts believe that NYSE:HIMS revenue will jump to over $1.2 billion this year followed by $1.5 billion in 2025, which could help justify its hefty valuation.
NYSE:HIMSLong
by DEXWireNews
HIMS a gender focused health care company LONGHIMS had an excellent earnings report for a small cap company; it is consumer driven quality focused and helps the customer feel good about him/her- self. It does not have any gender orientation agenda nor any obvious political inclinations. On the 120 minute chart, it started a moving averge convergence about a week before earnings. The Greeny TTM squeeze indicator did its thing as the post-earnings action began. I see this stock as a good long to hold into the next earnings and perhaps through it. HIMS is now at its all time high. There is no chart horizontal resistance overhead and traders will note that. I see the bullish momentum continuing perhaps with some healthy ( no pun intended) corrections while underway. Healthcare is considered to be a hot sector for 2024 this small cap seems to be warmed up.
NYSE:HIMSLong
by AwesomeAvani
RiskMastery's Breakout Stocks - HIMS EditionWelcome to RiskMastery's Breakout Stocks - Stocks with breakout potential. In this edition, we'll be looking at NYSE:HIMS ... I believe this code is at a point of potential volatility. If price can hold above $10.05 ... Bullish potential may be unlocked. My key upside targets include: - $11.24 (Conservative) - $12.47 (Medium) - $14.59 (Aggressive) If however price falls below $8.19 ... Bearish risk potential may be unlocked. (My key risk targets - C, M,& A - are as noted on the chart) Enjoy, and I look forward to being of further service into the future. If you'd like to connect, feel free to reach out and comment below. Mr RM | Risk Mastery Disclaimer: This post is intended for educational purposes only - Publicly available RiskMastery information & content is not intended to be financial advice in any shape or form. Please do your own research and seek advice from a licensed professional before acting on any of the information contained within this post. This post is not a solicitation or recommendation to buy, sell or hold any positions in any financial instrument. All demonstrated trades are merely incidental to the educational training RiskMastery aims to provide. You are solely responsible for your own investment and trading decisions, of which should be made only according to your own opinion, knowledge and experience. You should not rely on any of the information contained on this site or contained in any RiskMastery material on any website or platform. You assume the sole risk of any trade or investment you elect to make. RiskMastery and affiliates shall not be liable to you for any monetary losses or any other damages incurred directly or indirectly, from your use, reliance or reference of RiskMastery materials, content and educational information. Thank you for your understanding and cooperation - We look forward to working with you into the future to navigate the fine line of trading and investment success.
NYSE:HIMSLong
by Bullfinder-official
$HIMS - Which is it?NYSE:HIMS reached the wedge breakout target and is currently consolidating between the 50% and 38.2% Fib retracement levels. There is an inverse head and shoulders (IHS) forming, and the neckline happens to be the Point of Control (POC) volume resistance + 50% Fib retracement. It needs a successful breakout above $9.50 for the IHS to validate. However, there is also a mini Head and Shoulders forming. If materialized, it could lead to a fall to the $6 handle. So carefully watch the $8 area; if the price breaks below $8, the pattern will invalidate, and the stock could fall to the $7 - $6 area. So be aware of the risk. Upside targets: $9.50 $11.50 Downside risks: $7 to $6
NYSE:HIMSLong
by PaperBozz
Update on HIMs GAPThis Hims GAP play has worked out very well with some washouts that I had to hold through. You can see my entry with the dotted green line which I normally do for transparency. My entrance was after the confirmation of the breakout on that medium term downtrend (purple line) HIMs did have some issues in the meantime but the 8$ strike worked out great. I got all of the extrinsic value which is now intrinsic. My first price target was hit and the gap is almost completely closed. If you traded this same setup I hope you are mostly exited as Dec 15th ended calls are coming up. I like to sell calls 2-3 weeks before expiration so theta decay doesnt kill my gains. I generally buy 45-60 day out calls for this reason if I am going naked without cover.
NYSE:HIMSLong
by Apollo_21mil
Small bull flag on himsSmall caps accelerated on the CPI print as they had been lagging for months and were very oversold. As Hims fundamentals increase investors are catching on, TA wise the stock has taken two important levels this month and we have a half month to go. If this flag breaks to the upside we will see my first sell target that is the dashed green. Breaking the gold .382 is invalidation for shorter term calls. I am in dec 15th 8$ calls currently my entry marked by dotted green. RSI and HV continue to climb. We passed the .5 fib with conviction and are testing the .618 right now.
NYSE:HIMSLong
by Apollo_21mil
1
Hims breakout on 4 hour, will it break daily?This is a shorter term play that I have entered both in spot and in some calls for dec. 15th, the earnings report was good yesterday and the stock is showing strength. The breakout is confirmed on a 4 hour but I would like to see it on the daily as well. The local demand is small. This is the first double attempt at 20 SMA in a while as well. RSI is on a clear uptrend.The dotted green was my entry point yesterday. I expect this stock to rip at open and I have a GTC sell on spot at 9.2$. The calls I will play it by ear with stock alerts.
NYSE:HIMSLong
by Apollo_21mil
$HIMS - Watch out belowNYSE:HIMS - the recent double beat and guidance raise has not helped out this stock. There is a gap fill dating back to November of 2022 with hardly any strong support zones in sight. The death cross which just occurred should add further downward pressure to this already beaten up stock. I will turn long on NYSE:HIMS once the first level of support is reached (around $6.20). I will add on the way down as the stock approaches the gap fill. The increased guidance and double beat proves this may be a long-term winner, however, in the short-term there is more room to fall.
NYSE:HIMS
by jhuey235
Short Trade in HIMSThis is a potential short trade that could deliver a nice gain if the market pulls back. I am still focused on buying opportunities, but it never hurts to be prepared for the other side. Some of you may remember this as a stock I was looking to buy a couple months ago. Often times, the best short ideas come from stocks on my long watchlist that fail. HIMS tripled from October to April but began rolling over after a poor earnings report at the beginning of May. Not only did the stock fall on above-average volume, but even a 33% discount has failed to attract buyers. When stocks pull back, they either act as tennis balls (bounce back quickly) or eggs (splat and fail to rally). Buy tennis balls. Sell eggs. HIMS has formed a support shelf near the $8 level. A move below that would trigger a lot of stops, making it an ideal place to sell the stock short.
NYSE:HIMSShort
by rossgivens
2